A study suggested that COVID-19 patient with pneumonia produced more in vitro IL-17, which boosted the inflammation response and activated neutrophils in vitro CD4+ and CD8+ T cells produced more of IL-17 in patients with pneumonia. Here, CD4 is linked to susceptibility to pneumonia measurement.